

22 April 2022

Exide Life Insurance Company Limited  
3rd Floor, JP Techno Park,  
No. 3/1, Millers Road,  
Bangalore 560 001  
India

## **Willis Towers Watson Opinion on Embedded Value as at 31 March 2022**

Willis Towers Watson Actuarial Advisory LLP (“Willis Towers Watson”, “we”, “us” or “our”) has been engaged by Exide Life Insurance Company Limited (“Exide Life”, “the Company”, “you” or “your”) to review the embedded value prepared by Exide Life as at 31 March 2022 (“embedded value results”).

### **Scope of work**

Our scope of work covered:

- A review of the methodology and assumptions used to determine the embedded value results; and
- A review of the results of Exide Life’s calculation of the embedded value results.

### **Opinion**

Willis Towers Watson has concluded that the methodology and assumptions utilised by Exide Life to compute embedded value results and as reviewed by us comply with the standards issued by the Institute of Actuaries of India within the Actuarial Practice Standard 10 (“Indian Embedded Value Principles”) in all critical respects, and in particular that:

- the economic assumptions used are internally consistent and result in the projected cash-flows being valued in line with the prices of similar cash-flows that are traded on the capital markets;
- the operating assumptions have been set with appropriate regard to the past, current and expected future experience;
- the Required Capital has been determined and projected on the basis of minimum regulatory capital target of 150% of the Required Solvency Margin and has been assessed from a shareholder’s perspective;
- allowance has been made for the Cost of Residual Non-Hedgeable Risks; and
- for participating business, the assumed bonus rates and allocation of profit between policyholders and shareholders are consistent with projection assumptions, established Company practice and local market practice.

Willis Towers Watson has also performed high-level reasonableness checks on the results of the calculations by reviewing aggregate cashflows for each significant line of business, together with a number of further checks on the models, processes and results of the calculations performed by Exide Life. We have not, however, undertaken detailed checks of all models and actuarial processes involved. On the basis of this high-level review, Willis Towers Watson has confirmed that no material issues have been discovered that have a material impact on the aggregate embedded value as at 31 March 2022.

### **Willis Towers Watson Actuarial Advisory LLP**

Registered Office:  
A-210, Pioneer Urban Square  
Sector – 62, Golf Course Extension Road  
Gurugram 122003  
Haryana, India

T: +91 124 427 4047  
E: WTW.India.ICTLLP@willistowerswatson.com  
LLP Identification Number – AAL-3237

**Results**

Embedded Value is a measure of the consolidated value of shareholders’ interest in the life insurance business.

Exide Life has determined its embedded value based on a market consistent methodology. Under such an approach, embedded value is calculated as the present value of shareholders’ interests in the earnings distributable from the assets allocated to the business after allowance for the aggregate risks in the business.

Market consistent embedded value determined by Exide Life as at 31 March 2022 is set out in the table below:

**Table 1: Embedded Value as at 31 March 2022**

Amounts in INR millions  
*Figures may not be additive due to rounding*

Components of EV	31 March 2022
<b>Adjusted net worth</b>	<b>12,768</b>
Required capital	2,090
Free Surplus	10,678
<b>Value of in-force business</b>	<b>16,336</b>
Present value of future profits	17,230
Frictional cost of capital	(3)
Time value of financial options and guarantees	(22)
Cost of residual non-hedgeable risks	(869)
<b>Embedded Value</b>	<b>29,104</b>

**Disclaimers**

In arriving at our conclusions above, Willis Towers Watson has relied on data and information, including estimated impacts of any issues identified, provided by Exide Life shared on or prior to 21 April 2022 and do not take into account any developments after this date. This Opinion is made solely to Exide Life in accordance with the terms of Willis Towers Watson’s engagement letter dated 19 July 2021, supplemented by an addendum to the engagement letter, dated 29 September 2021. To the fullest extent permitted by applicable law, Willis Towers Watson does not accept or assume any responsibility, duty of care or liability to anyone other than Exide Life for or in connection with its review work, the opinions it has formed or for any statements set forth in this opinion.

COVID-19 is an ongoing and continuously evolving issue which has and will continue to have significant effects on global economic activity and insurance claims experience. The actual effects of COVID-19 could have an unexpected material impact on our findings. The level of uncertainty affecting our conclusions and the underlying volatility of actual outcomes is increased because of the emergence and contingent evolution of COVID-19.



Vivek Jalan, FIAI  
Partner




Kunj Behari Maheshwari, FIAI  
Partner